MetaVia’s DA-1726 48 mg Cohort Delivers 9.1% Weight Loss, Liver Improvements
MTVA•MetaVia’s 48 mg Phase 1 cohort achieved mean weight loss of 6.1% by day 26 and 9.1% by day 54, with waist circumference reduced by 9.8 cm, all without titration. Exploratory FibroScan data showed a 20 dB/m liver-fat decrease and 10.3% liver stiffness reduction versus placebo at day 54, backing MASH development.
1. Phase 1 Cohort Efficacy
In the randomized, double-blind Phase 1 multiple ascending dose study, nine obese but otherwise healthy adults in the 48 mg cohort achieved a mean 6.1% body-weight reduction at day 26 and 9.1% at day 54 versus placebo, with waist circumference declining by 5.8 cm at day 26 and 9.8 cm at day 54 without any dose titration.
2. Safety and Tolerability
DA-1726 was generally well tolerated at the 48 mg dose, with no serious adverse events or treatment discontinuations. Mild-to-moderate gastrointestinal events were transient and no clinically meaningful changes were observed in heart rate or QTcF despite glucagon receptor activation.
3. Exploratory Liver Assessments
Noninvasive FibroScan assessments at day 54 showed a 20 dB/m reduction in controlled attenuation parameter compared with a 24 dB/m increase in placebo and a 10.3% decrease in liver stiffness versus a 13.8% increase, along with directional FAST score improvements supporting further MASH evaluation.
4. Ongoing and Next Steps
MetaVia is advancing Phase 1 Part 3a/3b titration studies to assess extended higher-dose strategies, optimize tolerability, and evaluate the durability of metabolic and liver-related effects ahead of potential Phase 2 initiation.
